Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Farago

Showing results (451-460 of 493) with videos related to

Pageof 50
Sort By:
Clinical Lung Cancer|October 11, 2024
A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master ProtocolJ Spicer, N Blais, S Owen, et al.
Pharmaceuticals (Basel, Switzerland)|November 25, 2023
The Cardiorenal Effects of <i>Piper amalago</i> Are Mediated by the Nitric Oxide/Cyclic Guanosine Monophosphate Pathway and the Voltage-Dependent Potassium ChannelsLuciane M Monteiro, Lislaine M Klider, Aline A M Marques, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation studyD S Hong, T M Bauer, J J Lee, et al.
Cell|March 18, 2014
Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencingDavid G McFadden, Thales Papagiannakopoulos, Amaro Taylor-Weiner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 24, 2018
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLCJessica J Lin, Viola W Zhu, Adam J Schoenfeld, et al.
NPJ Precision Oncology|August 6, 2021
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumorsAaron S Mansfield, David S Hong, Christine L Hann, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2015
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung CancerAnna F Farago, Long P Le, Zongli Zheng, et al.
The Canadian Journal of Cardiology|April 30, 2013
Western Database of Lipid Variants (WDLV): a catalogue of genetic variants in monogenic dyslipidemiasJennifer Fu, Samantha Kwok, Leah Sinai, et al.
JCO Precision Oncology|January 16, 2018
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non-Small-Cell Lung CancerJustin F Gainor, Diane Tseng, Satoshi Yoda, et al.
JTO Clinical and Research Reports|September 30, 2021
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLCBiagio Ricciuti, Abdul Rafeh Naqash, Jarushka Naidoo, et al.
Pageof 50

Showing results (451-460 of 493) with videos related to

Sort By:
Pageof 50
Clinical Lung Cancer|October 11, 2024
A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master ProtocolJ Spicer, N Blais, S Owen, et al.
Pharmaceuticals (Basel, Switzerland)|November 25, 2023
The Cardiorenal Effects of <i>Piper amalago</i> Are Mediated by the Nitric Oxide/Cyclic Guanosine Monophosphate Pathway and the Voltage-Dependent Potassium ChannelsLuciane M Monteiro, Lislaine M Klider, Aline A M Marques, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation studyD S Hong, T M Bauer, J J Lee, et al.
Cell|March 18, 2014
Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencingDavid G McFadden, Thales Papagiannakopoulos, Amaro Taylor-Weiner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 24, 2018
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLCJessica J Lin, Viola W Zhu, Adam J Schoenfeld, et al.
NPJ Precision Oncology|August 6, 2021
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumorsAaron S Mansfield, David S Hong, Christine L Hann, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2015
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung CancerAnna F Farago, Long P Le, Zongli Zheng, et al.
The Canadian Journal of Cardiology|April 30, 2013
Western Database of Lipid Variants (WDLV): a catalogue of genetic variants in monogenic dyslipidemiasJennifer Fu, Samantha Kwok, Leah Sinai, et al.
JCO Precision Oncology|January 16, 2018
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non-Small-Cell Lung CancerJustin F Gainor, Diane Tseng, Satoshi Yoda, et al.
JTO Clinical and Research Reports|September 30, 2021
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLCBiagio Ricciuti, Abdul Rafeh Naqash, Jarushka Naidoo, et al.
Pageof 50